Philips Unveils Transcend Plus: Revolutionizing Cardiac Imaging
Philips Introduces Transcend Plus for Enhanced Cardiac Care
Philips, a leading global health technology company, has launched the Transcend Plus, a state-of-the-art upgrade for its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. This latest innovation promises to deliver impressive advancements in image quality, coupled with groundbreaking AI enhancements. As the demand for cardiac care continues to rise, the Transcend Plus aims to empower clinicians to make more informed, faster decisions based on enhanced imaging capabilities.
Revolutionizing Cardiac Imaging with AI
The Transcend Plus sets a new standard in echocardiography, providing next-generation 2D and 3D imaging. These upgrades allow clinicians to visualize cardiac anatomy and function with unprecedented clarity. The system boasts FDA-cleared enhancements that deliver superior imaging, crucial for accurate diagnoses, particularly in challenging cases.
Elevating Clinical Efficiency
With cardiac care becoming more complex due to increasing patient volumes and staffing shortages, Transcend Plus introduces an intelligent automation feature that assists clinicians in streamlining their workflows. This automation helps reduce the time spent on manual processes, allowing healthcare teams to focus more on patient care rather than administrative tasks.
Enhanced AI Applications and Their Importance
The integration of 26 FDA-cleared AI applications signifies Philips’ commitment to continuous innovation in cardiovascular imaging. These applications support the clinical staff by automating essential routines, making assessments quicker and more accurate across various healthcare settings, from echo labs to outpatient clinics. By enhancing operational consistency, these tools allow for improved patient management and outcomes.
Focus on Left Ventricular Function Assessment
Left ventricular function assessment is a pivotal aspect of cardiac imaging. The Transcend Plus is specially designed to enhance the precision of this assessment, leading to better diagnosis and monitoring of various cardiac conditions. Automated measurements minimize operator error, providing more reliable results in high-pressure clinical environments.
The system is capable of performing assessments even in cases where contrast agents cannot be used. With features like the 2D Auto EF and the advanced 2D Auto EF, providers can achieve accurate evaluations, making this technology essential for clinicians who handle diverse patient profiles.
The Impact of Transcend Plus on Clinical Practice
Transcend Plus is more than just an ultrasound system; it revolutionizes the way clinicians approach cardiac care. It equips medical professionals with the tools they need to deliver timely and precise care. The impact of sharper image quality coupled with advanced automation ensures that clinicians can efficiently manage growing patient loads without compromising their practice standards.
Philips has a noteworthy presence in the healthcare sector, performing approximately 1.33 billion diagnostic and interventional procedures every year, supporting the health of millions across the globe. The Transcend Plus will be showcased at notable conferences such as the European Society of Cardiology Congress and the American Society of Echocardiography annual meeting, where live demonstrations will highlight its capabilities.
Contact Information
For further inquiries regarding the Transcend Plus or Philips' cardiovascular products, please reach out to:
Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com
Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com
About Royal Philips
Royal Philips is a prominent health technology company dedicated to enhancing people's health through innovation. With a strong emphasis on developing solutions tailored for both consumers and healthcare providers, Philips aims to improve health outcomes in hospital and home settings. Boasting a significant workforce and a presence in over 100 countries, Philips continues to lead in diagnostic imaging and personal health solutions.
Frequently Asked Questions
1. What is Transcend Plus?
Transcend Plus is Philips' latest upgrade for its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems, incorporating advanced AI and imaging technology.
2. How does Transcend Plus improve cardiac imaging?
The system enhances 2D and 3D imaging quality, providing detailed visualization of cardiac anatomy and function, crucial for accurate diagnoses.
3. What are the benefits of AI integration in Transcend Plus?
AI applications streamline workflows, automate routine tasks, and enhance diagnostic precision, allowing for quicker and more consistent assessments.
4. Where will Transcend Plus be showcased?
Transcend Plus will be demonstrated at major medical conferences like the European Society of Cardiology Congress and the American Society of Echocardiography annual meeting.
5. Who can I contact for more information about Transcend Plus?
You can contact Kathy O’Reilly or Joost Maltha from Philips Global External Relations for further information.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
